News

The Economist1d
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...
Novo Nordisk Gains as CFO Touts Wegovy’s Rebound Potential
Novo Nordisk A/S trimmed its forecasts as sales of the drugmaker’s blockbuster obesity and diabetes medicines struggle with ...
Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales
Alternative compounded versions of Novo Nordisk’s blockbuster weight-loss and diabetes drugs have hurt its sales, ...
Pharmaceutical Technology on MSN1d
Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand
Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and ...
Novo Nordisk Stock Jumps Despite Full-Year Outlook Cut
U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered ...
Fierce Pharma1d
Novo's Wegovy takes a hit from compounders, but company expects faster second-half growth
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
Wegovy Deal Makes Cofounder Of Hair Loss Pill Seller Hims A Billionaire
Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...
Top Analyst Reports for Novo Nordisk, Honeywell & American Tower
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Honeywell ...